NT_1170x120_1-11-18

Johnson & Johnson

Johnson & Johnson to buy Momenta Pharmaceuticals for $6.5 billion

Johnson & Johnson to buy Momenta Pharmaceuticals for $6.5 billion

NEW BRUNSWICK, N.J. – Johnson & Johnson  announced that it has entered into a definitive agreement to acquire Momenta Pharmaceuticals (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 billion. The deal provides an opportunity for the Janssen Pharmaceutical Companies of Johnson & Johnson

Johnson & Johnson to discontinue talc-based Johnson’s Baby Powder in U.S. and Canada

Johnson & Johnson to discontinue talc-based Johnson’s Baby Powder in U.S. and Canada

NEW BRUNSWICK, N.J. — As part of a portfolio assessment related to COVID-19, in March, Johnson & Johnson Consumer Health announced on Tuesday that it has stopped shipping hundreds of items in the U.S. and Canada to prioritize high-demand products and to allow for appropriate social distancing in manufacturing and distribution facilities during this unprecedented

Johnson & Johnson is a leading candidate for COVID-19 vaccine

Johnson & Johnson is a leading candidate for COVID-19 vaccine

NEW BRUNSWICK, N.J. – Johnson & Johnson has announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020; the significant expansion of the existing partnership between the Janssen Pharmaceutical Companies of Johnson & Johnson and the Biomedical Advanced Research and Development Authority (BARDA); and the rapid scaling of

Johnson & Johnson expands partnership with BARDA

Johnson & Johnson expands partnership with BARDA

NEW BRUNSWICK, N.J. — Johnson & Johnson announced Tuesday that its Janssen Pharmaceutical Companies will expand its existing partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services, to seek treatment solutions for

Johnson & Johnson launches multi-pronged response to coronavirus

Johnson & Johnson launches multi-pronged response to coronavirus

NEW BRUNSWICK, N.J. — Johnson & Johnson announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a multi-pronged response to the novel coronavirus (also known as 2019-nCoV or Wuhan coronavirus) outbreak. As part of this work, the company has initiated efforts to develop a vaccine candidate against 2019-nCoV and broadly collaborate with others

Tylenol launches first new product in over a decade

Tylenol launches first new product in over a decade

BRUNSWICK, N.J. — For the first time in over ten years, Johnson & Johnson Consumer is introducing the first new form of Children’s Tylenol with the release of Children’s Tylenol Dissolve Packs. The new product is the only pediatric acetaminophen offered in an orally dissolving granular form.   The company said that its consumer research informed

Johnson & Johnson to appeal “flawed” opioid judgment in Oklahoma

Johnson & Johnson to appeal “flawed” opioid judgment in Oklahoma

NEW BRUNSWICK, N.J. – Johnson & Johnson and its Janssen Pharmaceutical Cos. announced they will appeal the $572 million civil judgment entered in Cleveland County District Court in the State of Oklahoma’s lawsuit against opioid manufacturers. The company is confident it has strong grounds to appeal this decision. The judgment disregards the Company’s compliance with

Johnson & Johnson completes deal for Ci:z Holdings Co.

Johnson & Johnson completes deal for Ci:z Holdings Co.

NEW BRUNSWICK, N.J. – Johnson & Johnson announced the completion of the acquisition of Ci:z Holdings Co. for a total purchase price of approximately ¥230 billion. The acquisition was completed through a series of transactions that included an all-cash tender offer to acquire publicly held shares of the Company for ¥5,900 per share.  Johnson & Johnson plans

J&J to participate in the Credit Suisse 27th Annual Healthcare Conference

J&J to participate in the Credit Suisse 27th Annual Healthcare Conference

NEW BRUNSWICK, N.J. — Johnson & Johnson  will participate in the Credit Suisse 27th Annual Healthcare Conference on Tuesday, November 13th, at The Phoenician in Scottsdale, AZ.  Scott White, group chairman, North America Pharmaceuticals will represent the company in a session scheduled at 8:35 a.m. (MST). This webcast will be available to investors and other interested

Johnson’s Baby disclosing 100% ingredient transparency

Johnson’s Baby disclosing 100% ingredient transparency

NEW YORK —Parents want to feel good about what they put on their baby’s skin — and so does Johnson’s Baby. That’s why the brand is disclosing 100% of the ingredients in its found in its baby products—including those found in fragrances. Fragrance has long been considered a trade secret, but Johnson’s recognizes that today’s

Johnson & Johnson Consumer to acquire Zarbee’s Inc.

Johnson & Johnson Consumer to acquire Zarbee’s Inc.

SKILLMAN, N.J. — Johnson & Johnson Consumer Inc. announced that it has entered into a definitive agreement to acquire Zarbee’s, Inc., a privately held company that is a leader in naturally-based healthcare products.  The acquisition will include the full line of Zarbee’s Naturals products for children and adults.  Financial terms of the transaction were not disclosed.

Walgreens launches online skincare advisor SkinID to aid acne sufferers

Walgreens launches online skincare advisor SkinID to aid acne sufferers

DEERFIELD, Ill. — Walgreens introduced an exclusive skincare analysis tool called SkinID on Walgreens.com to evaluate each customer’s skincare needs and build a personalized, three-step daily routine that will help banish breakouts. The cleansing, treatment and moisturizing products recommended are selected from Walgreens vast products across a variety of brands utilizing Johnson & Johnson Consumer

1 2 3